STAT+: Pharmalittle: We’re reading about FDA naming Pazdur as top drug regulator, a cancer drug gold rush, and more

The appointment of Richard Pazdur as the new director of CDER signifies a move towards stability in a crucial part of the FDA, addressing declining morale and significant staff departures. This change is important for medical professionals as it may lead to more consistent decision-making, potentially impacting drug approvals and patient care.